accurate answers
"A" rating Ans✓✓✓ drugs that are therapeutically equivalent to the
reference drug, with no known bioequivalence problems
"AB" rating Ans✓✓✓ therapeutically equivalent to each other; known
or potential bioequivalence problems may exist but have been found to
meet standards for bioequivalence
"B" rating Ans✓✓✓ not therapeutically equivalent to other
pharmaceutical products; actual or potential bioequivalence problems
have not been resolved
A1C Ans✓✓✓ glycosylated hemoglobin
normal <5.7%
prediabetes = 5.7% - 6.4%
diabetes >6.5%
A1C = BG
7=152
8-183
9=212
10=240
, AA Ans✓✓✓ conventional dosage forms
AN Ans✓✓✓ solutions and powders for aerosolization
AO Ans✓✓✓ Injectable oil solutions
AP Ans✓✓✓ injectable aqueous / IV solutions
AT Ans✓✓✓ topical products
B* Ans✓✓✓ requires FDA investigation to review equivalence
BC Ans✓✓✓ Extended-release dosage forms (capsules, injectables and
tablets)
BD Ans✓✓✓ active ingredient and dosage forms with
DOCUMENTED bioequivalence problems
BE Ans✓✓✓ delayed-release oral dosage forms
bioavailability Ans✓✓✓ refers to the rate and extent to which an active
ingredient is absorbed after administration and becomes available at the
drug's site of acction